1. Executive Summary
2. Global Dipeptidyl Peptidase IV Inhibitors Market Introduction
   2.1. Global Dipeptidyl Peptidase IV Inhibitors Market – Taxonomy
   2.2. Global Dipeptidyl Peptidase IV Inhibitors Market –Definitions
      2.2.1. Drugs
      2.2.2. Distribution Channel
3. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics
   3.1. Drivers
   3.2. Restraints
   3.3. Opportunities/Unmet Needs of the Market
   3.4. Trends
   3.5. Global Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Factors Impact Analysis
   3.6. Global Dipeptidyl Peptidase IV Inhibitors Market – Regulations
      3.6.1. US
      3.6.2. Europe
      3.6.3. Japan
   3.7. Global Dipeptidyl Peptidase IV Inhibitors Market – Product Pipeline Analysis
4. Global Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024
   4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
   4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
   4.3. Market Oppurtunity Analysis
5. Global Dipeptidyl Peptidase IV Inhibitors Market, By Drugs, 2013 - 2017 and Forecast, 2018 - 2024
   5.1. Sitagliptin
      5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.1.3. Market Opportunity Analysis
   5.2. Vildagliptin
      5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.2.3. Market Opportunity Analysis
   5.3. Saxagliptin
      5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.3.3. Market Opportunity Analysis
   5.4. Linagliptin
      5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.4.3. Market Opportunity Analysis
   5.5. Others
      5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      5.5.3. Market Opportunity Analysis
6. Global Dipeptidyl Peptidase IV Inhibitors Market Forecast, By Distribution Channel, 2013 - 2017 and Forecast, 2018 - 2024
   6.1. Hospital Pharmacies
      6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      6.1.3. Market Opportunity Analysis
   6.2. Retail Pharmacies
      6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      6.2.3. Market Opportunity Analysis
   6.3. On-line Pharmacies
      6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      6.3.3. Market Opportunity Analysis
7. Global Dipeptidyl Peptidase IV Inhibitors Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024
   7.1. North America
      7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.1.3. Market Opportunity Analysis
   7.2. Europe
      7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.2.3. Market Opportunity Analysis
   7.3. Asia-Pacific
      7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.3.3. Market Opportunity Analysis
   7.4. Latin America
      7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.4.3. Market Opportunity Analysis
   7.5. Middle East and Africa
      7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      7.5.3. Market Opportunity Analysis
   7.6. Global Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel, and Region, 2018 – 2024
8. North America Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   8.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      8.1.1. Sitagliptin
      8.1.2. Vildagliptin
      8.1.3. Saxagliptin
      8.1.4. Linagliptin
      8.1.5. Others
   8.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      8.2.1. Hospital Pharmacies
      8.2.2. Retail Pharmacies
      8.2.3. On-line Pharmacies
   8.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      8.3.1. US
      8.3.2. Canada
   8.4. North America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   8.5. North America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
9. Europe Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   9.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      9.1.1. Sitagliptin
      9.1.2. Vildagliptin
      9.1.3. Saxagliptin
      9.1.4. Linagliptin
      9.1.5. Others
   9.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      9.2.1. Hospital Pharmacies
      9.2.2. Retail Pharmacies
      9.2.3. On-line Pharmacies
   9.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      9.3.1. Germany
      9.3.2. UK
      9.3.3. France
      9.3.4. Spain
      9.3.5. Italy
      9.3.6. Russia
      9.3.7. Poland
      9.3.8. Rest of Europe
   9.4. Europe Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   9.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
10. Asia-Pacific Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   10.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      10.1.1. Sitagliptin
      10.1.2. Vildagliptin
      10.1.3. Saxagliptin
      10.1.4. Linagliptin
      10.1.5. Others
   10.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      10.2.1. Hospital Pharmacies
      10.2.2. Retail Pharmacies
      10.2.3. On-line Pharmacies
   10.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      10.3.1. Japan
      10.3.2. China
      10.3.3. India
      10.3.4. ASEAN
      10.3.5. Australia & New Zealand
      10.3.6. Rest of Asia-Pacific
   10.4. Asia-Pacific Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   10.5. Europe Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
11. Latin America Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   11.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      11.1.1. Sitagliptin
      11.1.2. Vildagliptin
      11.1.3. Saxagliptin
      11.1.4. Linagliptin
      11.1.5. Others
   11.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      11.2.1. Hospital Pharmacies
      11.2.2. Retail Pharmacies
      11.2.3. On-line Pharmacies
   11.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      11.3.1. Brazil
      11.3.2. Mexico
      11.3.3. Argentina
      11.3.4. Venezuela
      11.3.5. Rest of Latin America
   11.4. Latin America Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   11.5. Latin America Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
12. Middle East and Africa Dipeptidyl Peptidase IV Inhibitors Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
   12.1. Drugs Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      12.1.1. Sitagliptin
      12.1.2. Vildagliptin
      12.1.3. Saxagliptin
      12.1.4. Linagliptin
      12.1.5. Others
   12.2. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      12.2.1. Hospital Pharmacies
      12.2.2. Retail Pharmacies
      12.2.3. On-line Pharmacies
   12.3. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      12.3.1. Gulf Cooperation Council (GCC) Countries
      12.3.2. Israel
      12.3.3. South Africa
      12.3.4. Rest of MEA
   12.4. MEA Dipeptidyl Peptidase IV Inhibitors Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2018 – 2024
   12.5. MEA Dipeptidyl Peptidase IV Inhibitors Market Dynamics – Trends
13. Competition Landscape
   13.1. Strategic Dashboard of Top Market Players
   13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      13.2.1. AstraZeneca Plc. (UK)
      13.2.2. Boehringer Ingelheim GmbH (Germany)
      13.2.3. Eli Lilly and Company (U.S.)
      13.2.4. Merck & Co, Inc. (U.S.)
      13.2.5. Mitsubishi Tanabe Pharma Corporation (Japan)
      13.2.6. Novartis AG (Switzerland)
      13.2.7. Takeda Pharmaceutical Company Limited (Japan)
      13.2.8. Sanofi (France)
      13.2.9. Bristol-Myers Squibb (U.S.)
      13.2.10. GlaxoSmithKline Plc. (U.K.)
      13.2.11. Pfizer, Inc. (U.S.)
      13.2.12. Otsuka Holdings Co. Ltd. (Japan)
      13.2.13. Ornamed Pharmaceutical, Inc. (Israel)
      13.2.14. Dr. Reddy’s Laboratories, Ltd. (India)
      13.2.15. Novo Nordisk A/S (Denmark)
14. Research Methodology
15. Key Assumptions and Acronyms